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ABSTRACT
Mice deficient for Id2, a negative regulator of basic
helix–loop–helix (bHLH) transcription factors, exhibit
a defect in lactation due to impaired lobuloalveolar
development during pregnancy, similar to the
mice lacking the CCAAT enhancer binding protein
(C/EBP) b. Here, we show that Id2 i sad i r e c tt a r g e to f
C/EBPb. Translocation of C/EBPb into the nucleus,
which was achieved by using a system utilizing the
fusion protein between C/EBPb and the ligand-
binding domain of the human estrogen receptor
(C/EBPb-ERT), demonstrated the rapid induction of
endogenousId2 expression.In reporter assays, trans-
activationoftheId2promoterbyC/EBPbwasobserved
and, among three potential C/EBPb binding sites
foundinthe2.3kbId2promoterregion,themostprox-
imal element was responsible for the transactivation.
Electrophoretic mobility shift assay (EMSA) identified
this element as a core sequence to which C/EBPb
binds. Chromatin immunoprecipitation (ChIP) further-
more confirmed the presence of C/EBPb in the Id2
promoter region. Northern blotting showed that Id2
expression in C/EBPb-deficient mammary glands
was reduced at 10 days post coitus (d.p.c.), compared
withthatinwild-typemammaryglands.Thus,ourdata
demonstrate that Id2 is a direct target of C/EBPb and
provideinsightintomolecularmechanismsunderlying
mammary gland development during pregnancy.
INTRODUCTION
Transcription factors play a pivotal role in gene networks that
control various events related to differentiation, proliferation
andresponsestoextra-andintracellularstimuli.Tounderstand
the molecular bases underlying complex biological processes,
it is essential to elucidate the functional relationships of tran-
scription factors and their regulators that are involved in a
process of interest.
The mammary gland provides a good experimental model
system to investigate mechanisms underlying cell prolife-
ration, differentiation, apoptosis and tissue remodeling (1).
In pregnancy, under the inﬂuence of various hormones and
growth factors, mammary epithelial cells undergo rapid pro-
liferation and subsequent differentiation into an expanded
glandular structure via the process of lobuloalveolar develop-
ment (1). Loss-of-function experiments in mice have revealed
several genes that are involved in the distinct steps of mam-
mary gland development (2). These genes include not only
nuclear hormone receptors, i.e. the estrogen receptor and pro-
gesterone receptor, but also other transcription factors and cell
cycle regulators (2).
Id proteins are negative regulators of basic helix–loop–helix
(bHLH) transcription factors that are exempliﬁed by MyoD
and Neurogenin (3). They have a helix–loop–helix (HLH)
motif but lack a DNA-binding domain. Due to these structural
features, Id proteins dimerize with bHLH factors (mainly with
ubiquitously expressed bHLH factors known as E proteins) in
a dominant-negative manner, and prevent bHLH factors from
forming hetero- and homodimers (3). Four members of the Id
protein family, Id1 through Id4, have been identiﬁed in mam-
mals (3). Since bHLH factors are involved in the regulation of
multiple processes of cell differentiation, proliferation and
cellular functions, Id proteins also participate in these biolo-
gical situations. We previously reported that mice deﬁcient for
Id2 show a lactation defect due to impaired lobuloalveolar
development of the mammary gland during pregnancy (4).
Theobserveddefectisduemostlytothe impaired proliferation
and enhanced apoptosis of mammary epithelial cells in the
early and late phases of pregnancy, respectively (4).
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transcription factors bearing a basic leucine zipper motif.
Six members of the family, C/EBPa, C/EBPb, C/EBPg,
C/EBPd, C/EBPe and C/EBPz, have been identiﬁed, and
homo- and heterodimers formed by the members and their
isoforms generated by differential usage of the start codon
(5–7). C/EBPs act as important regulators of cellular differ-
entiation, proliferation and function in a variety of tissues
(5–7). Mice deﬁcient for C/EBPb, also known as NF-IL6
(8), display impaired lobuloalveolar development, which is
associated with perturbed proliferation of mammary epithelial
cells in the early phase of pregnancy (9,10), as in the case of
Id2-null mice (4). Elevated expression of the progesterone
receptor in mammary epithelial cells is found in both these
types of null mutant mice (4,11).
To understand the molecular mechanisms underlying
pregnancy-induced mammary gland development, we invest-
igated the relationship between Id2 and C/EBPb, and found
that Id2 is under the control of C/EBPb. Our present work
revealedagene networkthatregulates normalmammarygland
development in response to gestation.
MATERIALS AND METHODS
Mice and animal experiments
Both Cebpb mutant and Rag2 mutant mice were maintained
under speciﬁc pathogen-free conditions. Transplantation of
mammary glands to Rag2-null mice and whole mount staining
of mammary glands with carmine were done as described
previously (4). All experimental procedures followed the
guidelines of University of Fukui for animal experiments.
Plasmid construction
pC/EBPb-ERT and pC/EBPb-6Myc were constructed with
fragments corresponding to nucleotides 897–994 and 1–994
of the mouse Cebpb cDNA, respectively, that were ampliﬁed
by PCR with pMSV-C/EBPb (12) as a template. For pC/
EBPb-ERT, the PCR fragment was used to substitute the
corresponding region of pMSV-C/EBPb and the XhoI–
EcoRI fragment (the region encoding the human estrogen
receptor ligand-binding domain, ERT) of pBS-ERT2 (gift
from T. Nakano) was inserted into the XhoI and EcoRI
sites of the resultant plasmid. For pC/EBPb-6Myc, the endo-
genous NheI site present in the end of the coding region of the
Cebpb cDNA was changed to BamHI or XhoI sites by using
appropriate reverse primers. pC/EBPb-6Myc was generated
by inserting the ampliﬁed fragment into the SmaI and
BamHI sites of pCMV-6Myc (13).
Construction ofa series of reporter plasmids bearing various
lengths of the Id2 promoter was done using pGL2-basic
(Promega) and the plasmid pBS-Eco10K, which harbors a
mouse genomic fragment ( 10 kb) containing the whole Id2
gene locus (14). Endogenous restriction sites for BamHI,
HindIII, SmaI and SacI in the Id2 promoter region were util-
ized to generate pGL2-Id2/A, pGL2-Id2/C, pGL2-Id2/D and
pGL2-Id2/E, respectively. Plasmids pGL2-Id2/F and pGL2-
Id2/G were generated by subcloning the corresponding PCR
fragments prepared with appropriate primer sets into pGL2-
basic. Reporter plasmids bearing proximal deletion mutants,
pGL2-Id2/E D1through D3, were generated by substituting the
EcoRI–ApaLI fragment of pGL2-Id2/E with mutated frag-
ments prepared by annealing synthesized sense and antisense
oligonucleotides. All the reporter constructs contained the seq-
uence 50 to the translation start codon of the Id2 gene, includ-
ing the endogenous TATA box. Authenticity of the plasmids
was veriﬁed by sequencing.
Cell cultures and DNA transfection
NIH3T3 cells were maintained in DMEM supplemented with
10% fetal calf serum plus 100 U/ml penicillin and 100 mg/ml
streptomycin. For transient transfection, NIH3T3 cells were
plated at densities of 4 · 10
4 cells/1.6-cm well or 1 · 10
6 cells/
10-cm dish 24 h before transfection. Transfections were per-
formed by the lipofection method using TransIT-LT1
TM (Pan
Vera Corp.) according to the manufacturer’s instructions.
Establishment of a cell line constitutively expressing
a C/EBPb-ERT chimeric protein
NIH3T3 cells were co-transfected with pPGKneo (15) and pC/
EBPb-ERT using the calcium-phosphate DNA coprecipitation
method in a molar ratio of 1:10. One day after transfection,
the cells were subjected to neomycin selection for 10 days.
Neomycin-resistant clones were transferred to 96-well plates
and C/EBPb protein expression were evaluated by immuno-
staining with polyclonal anti-C/EBPb Ab (C-19) (Santa Cruz
Biotechnology). Nuclear translocation of the C/EBPb-ERT
chimeric protein was induced by treating the cells with
1 mM 4-hydroxytamoxifen (4HT) (Sigma).
Northern blot analysis
Total RNA was extracted from cultured cells and mouse
organs using an RNeasy kit (QIAGEN) according to the man-
ufacturer’s instructions. Ten to twenty micrograms of total
RNA were separated by electrophoresis on a 1.0% agarose–
formaldehyde gel, transferred onto nylon ﬁlters, and cross-
linked in a UV chamber. Radioactive DNA probes for Id2,
b-actin (Actb) and cytokeratin 18 (Cyk18) were prepared by
random-primed labeling of the mouse Id2, Actb and Cyk18
cDNAs with a-[
32P]dCTP, respectively. Hybridization and
washing were performed under high-stringency condition.
The ﬁlters were exposed to X-ray ﬁlms with an intensifying
screen or an imaging plate for BAS2000 (Fuji Film) to
calculate the radioactivity.
Luciferase assay
UsingtheDual-Luciferase
TMreporterassaysystem(Promega),
total cell lysates were prepared 48 h after transfection and
luciferase assays were performed as described (13). As an
internal control to normalize ﬁreﬂy luciferase activity, the
PGK promoter-driven sea-pansy luciferase plasmid, pRL-
PGK, which was constructed by inserting the PGK promoter
into pRL-null (Promega), was used. Total light produc-
tion was measured with a Luminescencer-JHR (ATTO) or
Luminescencer-PSN (ATTO).
Nuclear extracts preparation, EMSA and western
blot analysis
Nuclear extracts of NIH3T3 cells were prepared, as described
previously (16). The protein content was determined using the
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leotides labeled with a-[32P]dCTP using the Klenow fragment
were reacted with 5 mg of nuclear extract and separated on a
6.0% polyacrylamide gel, as described previously (17). The
sequence of the HpxA oligonucleotide was 50-GATCC-
TATTTGCAGTGATGTAATCAGCG-30 (18). For the inhibi-
tion assay, a 200-fold excess of unlabeled competitor
oligonucleotide was added in the reaction. Competitor oligo-
nucleotides were synthesized according to the sequences
reported previously: Oct, YY and NF-Y (19), Myb (20),
Sox (21) and NF-kB (22). For the supershift assay, 2 mgo f
rabbit polyclonal IgG Ab (Ab) against c-Myc (A-14) (Santa
Cruz Biotechnology) was preincubated with the nuclear
extracts for 30 min at room temperature and the mixture
was subjected to EMSA. Western blot analysis was done
essentially as described previously (13). Antibodies used
were anti-c-Myc (A-14) (Santa Cruz Biotechnology) and
anti-C/EBPb (C-19) (Santa Cruz Biotechnology).
ChIP assay
The ChIP assay was done as described previously (23), with
the following modiﬁcation. NIH3T3 cells ( 2 · 10
6 cells)
were transfected with 12 mg of pC/EBPb-6Myc using the
FuGENE 6 reagent (Roche Molecular Biochemicals), accord-
ing to the manufacturer’s instructions, and incubated for 48 h.
After cross-linkage with 1% formaldehyde in the medium for
2 min at 37 C, cells were rinsed with ice-cold PBS twice,
resuspended in 1 ml of SDS lysis buffer (23), and incubated
on ice for 10 min. Cell lysates were then sonicated with a
Bioruptor (Cosmo Bio) for 30 s at the maximum setting eight
times with 1-min intervals, yielding chromatin fragments
between 100 and 500 bp in size. The sonicated lysates were
centrifuged for 10 min and the resulting supernatants were
diluted in 1.8 ml of ChIP dilution buffer (23) and precleared
by adding 30 ml of protein A-Sepharose supplemented with
100 mg/ml salmon sperm DNA at 4 C for 1 h. Immunoprecip-
itation was performed with 5 mg of polyclonal anti-Myc Ab
(A-14) or anti-C/EBPb Ab (C-19) (Santa Cruz Biotechnology)
at 4 C for 2 h. As controls, we omitted Ab or included normal
rabbit IgG (Sigma). Immune complexes were then mixed with
30 ml of protein A-Sepharose at 4 C for 2 h and washed
sequentially with low salt buffer, high salt buffer and LiCl
wash buffer (23). After precipitates were washed with TE and
extracted with elution buffer, reversal of cross-linking and
puriﬁcation of DNA were done as described (23). Precipitated
DNA was resuspended in 100 ml of TE for input DNA and
20 ml of TE for ChIP DNA. Obtained DNA fragments were
analyzed by PCR using the following primer pairs: Id2,
forward, 50-GAATTCGCCTGGTATGATGGACGG-30 and
reverse,50-ATGTTGTAGAGCAGACTCATCGGG-30;IGF-1,
forward, 50-GTCTGCTAACCCTGTCAGAGACAC-30 and
reverse, 50-GGCTCTATCTGCTCTGAATTTAGC-30.
RESULTS
Induction of endogenous Id2 gene expression
by C/EBPb
To determine if exogenous C/EBPb expression can trans-
activate the endogenous Id2 gene expression, we established
a stable line of NIH3T3 cells expressing the fusion protein
of C/EBPb with the ligand-binding domain of human estro-
gen receptor (C/EBPb-ERT). The C/EBPb-ERT protein is
sequestered in the cytoplasm by heat shock proteins and the
application of 4-hydroxytamoxifen (4HT) to the cells induces
rapid translocation of C/EBPb-ERT from the cytoplasm to the
nucleus (24), which enables us to follow the effect of C/EBPb
on gene expression. As shown in Figure 1, the level of Id2
mRNA was increased by >2-fold in a biphasic manner, show-
ing a sharp peak at 30 min and a broad rise in the later phase,
after the additionof 4HT. In contrast, Id2 mRNA expression in
the parentalNIH3T3 cellswas not changedsigniﬁcantly by the
treatment (Figure 1). This indicates that the endogenous Id2
gene expression is induced by C/EBPb. The observed rapid
and biphasic changes in the Id2 mRNA level after the 4HT
treatment suggested the short half-life of Id2 mRNA and a
complex regulation of the endogenous Id2 gene expression by
C/EBPb.
Figure 1. Induction of endogenous Id2 expression by the C/EBPb-ERT fusion
protein. A permanent cell line expressing C/EBPb-ERT was established with
NIH3T3 cells and treated with 1 mM 4HT to induce the translocation of the C/
EBPb-ERTfusionproteinfromthecytosol.RNAwasextractedfromthecellsat
varioustimesandsubjectedtonorthernblotanalysis.Representativeresultsare
shown in (A). The probes used are indicated on the left of each panel. Relative
Id2expressionisshownin(B).Actbexpressionwasusedasaninternalcontrol.
Each Id2 mRNA level is expressed as fold increase, compared to that in cells
incubatedwithout4HT.WhiteandblackbarsindicaterelativeId2mRNAlevels
intheparentalNIH3T3cellsandNIH3T3cellsstablyexpressingC/EBPb-ERT,
respectively. Results are shown as the mean and standard error values of the
mean (n = 3).
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the proximal promoter region
We next examined whether the promoter region of the Id2
gene contains the C/EBPb consensus binding site, TT/GNNG-
NAAT/G (8), and found three potential sites at positions  445
to  436,  81 to  73 and  73 to  65 (designated C/EBPb
related element CbE1, CbE2 and CbE3, respectively), as
shown in Figure 2. In addition, a luciferase reporter construct
containing the upstream region of the Id2 gene, spanning from
 2248 to +84 relative to the transcription initiation site,
showed a 2.5-fold increase in activity in NIH3T3 cells co-
transfected with a C/EBPb expression vector, indicating that
the Id2 promoter is responsive to the transcription factor
(Figure 2). We then constructed a series of deletion mutants
of the Id2 promoter and analyzed their activities in response to
C/EBPb using the same system. Deletion of the promoter
region from  2248 to  101 bp resulted in retention of the
responsiveness of the promoter to C/EBPb, while further
deletion from positions  100 to  40 abolished the response
to C/EBPb. These results demonstrated that the C/EBPb-
responsive element resides in the region containing CbE2
and CbE3 that spans  100 to  40 bp in the Id2 promoter.
C/EBPb binds directly to the Id2 promoter sequence
containing its consensus binding sites
To examine whether the transactivation of the Id2 promoter by
C/EBPbisdirectorindirect,wenextperformedanEMSAusing
oligonucleotide probes derived from the Id2 promoter region.
As the reporter assay demonstrated that the region spanning
positions  100 to  40 from the transcription initiation site is
responsible for the transactivation of the Id2 promoter by
C/EBPb,wedesignedfouroligonucleotidestocoverthisregion
in an overlapping manner (Figure 3A). Nuclear extracts were
prepared from NIH3T3 cells transfected with an expression
vector of C/EBPb tagged with 6xMyc or its parental vector.
As shown in Figure 3A (lanes 1–3), three retarded bands were
detected with an oligonucleotide derived from the promoter of
theHpxAgene,whichisoneofthedirecttargetsofC/EBPb(18).
It is known that a single Cebpb mRNA can generate three iso-
formsoftheC/EBPbprotein,liver-enrichedactivatingproteins
(LAP1 and LAP2) and liver-enriched inhibitory protein (LIP),
through leaky ribosomal scanning (7,18,25). Western blot
analysis conﬁrmed that transient transfection with the vectors
of untagged C/EBPb or 6xMyc-tagged C/EBPb leads to the
expression of the three isoforms in NIH3T3 cells, while endo-
genous C/EBPb proteins were barely detectable in the parental
NIH3T3cells(Figure3B).Therefore,accordingtotheprevious
report (25), the detected bands seemed to correspond to dimers
ofLAP/LAP,LAP/LIPandLIP/LIP,asindicatedinFigure3A.
Similarly,probeIIcontainingtheregioncoveringpositions 95
and  56 demonstrated the binding of C/EBPb (lanes 7–9 in
Figure3A).Inbothcases,inclusionofAbagainsttheMyc-tagor
C/EBPb (data not shown) caused supershift of the retarded
bands, demonstrating the speciﬁcity of the reaction. Further-
more, the formation of protein–DNA complexes with probe II
wasblockedbycompetitionwitha200-foldmolarexcessofthe
cold HpxA oligonucleotide (lanes 16 and 17 in Figure 3A),
although, as detected in lanes 7–9, nonspeciﬁc binding at the
position of LAP/LAP was observed with nuclear extracts of
both non-transfectants and transfectants of pC/EBPb-6Myc
(lanes 16 and 17). In contrast to the binding to probe II, no
speciﬁc binding was detected in EMSA with probes I, III and
IV (lanes 4–6 and 10–15 in Figure 3A). These results sugges-
ted that C/EBPb binds directly to the Id2 promoter via CbE2
and CbE3.
To delineate the binding site of C/EBPb more precisely,
we synthesized ﬁve oligonucleotides bearing deletions or
Figure 2. TransactivationoftheId2promoterbyC/EBPb.IntheId2promoterregionspanningpositions 2248to+84fromthetranscriptioninitiationsite,thereare
three potential C/EBPb binding sites, named CbE1 ( 445 to  436), CbE2 ( 81 to  73) and CbE3 ( 73 to  65), as indicated by arrows in the schematic
representation of pGL2-Id2/A. The numbers shown on the left of the respective reporter constructs indicate the positions from the transcription initiation site. The
sequencecomparisonofthesesiteswiththeconsensusbindingsite(8),TT/GNNGNAAT/G,isshownintheinset.Inthereporterassay,eachofthereporterplasmids,
which contained various lengths of the Id2 promoter, was co-transfected into NIH3T3 cells with pPGK-renilla, together with pMSV-C/EBPb or pMSV-mock, as
indicatedby+and ,respectively,inthemiddle,andluciferaseactivitiesweredeterminedafter48h.Luciferaseactivitiesoftherespectivereporterconstructswere
determined by normalizing by the respective renilla luciferase activity. Fold induction of luciferase activity by C/EBPb is indicated on the right. The mean and
standard error of the mean values of three independent experiments are shown.
Nucleic Acids Research, 2005, Vol. 33, No. 6 1927mutations in the domain related to CbE2 and/or CbE3, and
performed EMSA. As shown in Figure 3C, C/EBPb bound
normally to oligonucleotides D1 and m1 (lanes 7–10), which
had a deletion and base substitutions in CbE2, respectively. In
addition, C/EBPb formed a complex with oligonucleotide D2
(lanes 11 and 12 in Figure 3C), in which the spacer between
CbE2 and CbE3 was deleted. On the other hand, deletion and
base substitutions in CbE2 (oligonucleotides D3 and m2, res-
pectively) failed to form a retarded complex with C/EBPb
(lanes 13–16 in Figure 3C). These results strongly suggest
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low sequence conservation with the C/EBPb consensus bind-
ing site (inset in Figure 2).
CbE3 contains sequences that are similar to the consensus
binding sites of other transcription factors including NF-Y,
NF-kB, Sox, Oct, YY and Myb. To exclude the possibility
that the retarded bands shown in Figure 3A and C contain
these transcription factors, we performed competitive EMSA
using the oligonucleotides that contain the consensus binding
sites of these transcription factors. As shown in Figure 3D,
none of the oligonucleotides competed for nor altered the
retarded bands generated by probe II and the nuclear extract
oftransfectantsofpC/EBPb-6Myc(lanes1and3–8),whilethe
HpxA oligonucleotide did (lane 2). Therefore, it is unlikely
that transcription factors other than C/EBPb bind CbE3
directly or indirectly.
Transactivation by C/EBPb depends on CbE3
To conﬁrm that CbE3 is responsible for the transactivation of
the Id2 promoter by C/EBPb, we constructed three reporter
plasmids, pGL2-Id2/ED1, pGL2-Id2/ED2 and pGL2-Id2/ED3,
with deletion of both CbE2 and CbE3, CbE2 or CbE3, res-
pectively, and transfected them with or without a C/EBPb
expression vector into NIH3T3 cells. As shown in Figure 4,
pGL2-Id2/ED2 expressed luciferase activity comparable to
that of the wild-type pGL2-Id2/E plasmid, whereas no appre-
ciable response to C/EBPb was observed with pGL2-Id2/ED1
or pGL2-Id2/ED3. These results, together with the data shown
in Figure 3B, indicate that the regulation of Id2 expression by
C/EBPb occurs via the most proximal CbE in the Id2 promo-
ter region.
Direct binding of C/EBPb to the endogenous
Id2 promoter
We next performed the chromatin immunoprecipitation
(ChIP) assay to demonstrate that C/EBPb is present on the
Id2 promoter region containing CbE2 and CbE3. To do this,
NIH3T3 cells were transfected with the C/EBPb-6xMyc
expression vector and the cell lysate prepared after ﬁxation
was precipitated with an Ab against Myc or C/EBPb, followed
by PCR with primers for the Id2 promoter. As shown in
Figure 5 (lanes 9 and 10), both antibodies enriched the
chromatin-containing DNA of the Id2 promoter region com-
pared to incubation with normal rabbit IgG or without Ab
(lanes 7 and 8), similar to the case of the insulin-like growth
factor-1 (Igf1) gene, which is known to be a direct downstream
target of C/EBPb (26). On the other hand, no such enrichment
was detected in cells transfected with the parental expression
vector (Figure 5, lanes 2–5). These data indicate that C/EBPb
is bound to the endogenous Id2 promoter.
Reduced expression of Id2 in C/EBPb-deficient
mammary glands during pregnancy
We ﬁnally examined Id2 gene expression in pregnant mam-
mary glands of C/EBPb-null mice during pregnancy. Since
C/EBPb-null mice are infertile, we transplanted mammary
epithelial cells into the inguinal fat pads of Rag2-null mice
in which mammary glands had been precleared by removing
mammary glands of the host at the age of 3 weeks (4). After 7
weeks of transplantation, mice were mated with male mice
and RNA was puriﬁed from the mammary glands at 10 days
post coitus (d.p.c.). In morphological examination, mammary
glands were successfully reconstituted in all recipients and the
impaired proliferation of mammary epithelial cells was
observed in the gland reconstituted with C/EBPb-null mam-
mary epithelial cells, as expected (Figure 6A). Northern blot
analysis demonstrated that, in the non-pregnant state, there
was no signiﬁcant difference in the basal expression level
of Id2 between mammary glands reconstituted with mammary
epithelial cells of C/EBPb-null mice and those reconstituted
with cells of wild-type mice. In contrast, mammary glands
reconstituted with C/EBPb-null mammary epithelial cells
were devoid of the pregnancy-induced elevation of Id2
mRNA expression. Thus, it was suggested that Id2 expression
is under the inﬂuence of C/EBPb in mammary glands during
pregnancy, but not in the non-pregnant state.
DISCUSSION
Mammary gland development is divided into several stages
that are related to sexual development and reproduction: the
embryonic, prepubertal, pubertal, pregnancy, lactation and
involution stages (2). Each stage shows distinct requirements
for speciﬁc genes for completion of the stage and/or pro-
gression to the next stage, as revealed or conﬁrmed by gene
inactivation studies in mice (2). Among these stages, the preg-
nancy stage, where robust proliferation and differentiation of
mammary epithelial cells lead to lobuloalveolar development,
is controlled by various molecules including the prolactin
receptor, Stat5, receptor activator of NF-kB (RANK), receptor
activator of NF-kB ligand (RANKL), cyclin D1, C/EBPb and
Figure 3. EMSA for C/EBPb with the Id2 promoter. EMSA was performed with
32P-labeled probes and nuclear extracts obtained from NIH3T3 cells transiently
transfectedwithpC/EBPb-6MycorparentalNIH3T3cells.OligonucleotideHpxAwasusedasapositivecontrolforC/EBPbbinding.DNA–proteincomplexeswere
separatedona6%polyacrylamidegel,andthegelwasdriedandexposedtoX-rayfilm.ThreeretardedbandsderivedfromdimersofC/EBPbisoformsareindicated
byfilledarrowheads(LAP/LAP,LAP/LIPandLIP/LIP).Thesupershiftedbandformedwithanti-MycAbisindicatedbyanopenarrowhead.(A)Onthetop,probes
used in EMSA are aligned with their positions in the Id2 promoter sequence. Arrows indicate the positions of CbE2 and CbE3. The probes used were HpxA (lanes
1–3),probeI(lanes4–6),probeII(lanes7–9),probeIII(lanes10–12)andprobeIV(lanes13–15).NuclearextractswerepreparedfromNIH3T3cellstransfectedwith
pC/EBPb-6Myc (lanes 2, 3, 5, 6, 8, 9, 11, 12, 14, 15) or the parental NIH3T3 cells (lanes 1, 4, 7, 10, 13). For the detection of a supershifted band, anti-Myc Ab was
included in the incubation mixture (lanes 3, 6, 9, 12, 15). In lanes 16 and 17, a 200-fold molar excess of the HpxA oligonucleotide was added as cold competitor.
(B) Expression of C/EBPb isoforms in NIH3T3 cells. Left and right panels show the results with anti-C/EBPb and anti-Myc Abs, respectively. Origins of nuclear
extractsareshownonthetop.PositionsoftherespectiveC/EBPbisoformsareindicatedbyarrowheads(untagged-C/EBPb)andarrows(6Myc-tagged-C/EBPb)on
therightofeachpanel.Positionsofsizemarkersareindicatedontheleftofeachpanel.(C)MutantoligonucleotidesdesignedbasedonprobeIIwereusedinEMSA.
The positions of CbE2 and CbE3 are indicated by arrows. Probes D1 and D3 are CbE2 and CbE3 deletion mutants of probe II, respectively. Deleted regions are
indicated by dashes. Base-substituted regions are underlined.The probes used were HpxA (lanes 1–3), probe II (lanes 4–6), D1 (lanes 7 and 8), m1 (lanes 9 and 10),
D2(lanes11and12),D3(lanes13and14)andm2(lanes15and16).NuclearextractswerepreparedfromNIH3T3cellstransfectedwithpC/EBPb-6Myc(lanes2,3,
5–16)ortheparentalNIH3T3cells(lanes1and4).Forthedetectionofasupershiftedband,anti-MycAbwasincludedintheincubationmixture(lanes3,6,8,12,14
and 16). (D) 32P-labeled probe II was incubated with nuclear extracts containing C/EBPb-6Myc, together with 200-fold molar excess of the cold competitors that
contain the binding sites of the transcription factors as indicated on the top (see Materials and Methods).
1930 Nucleic Acids Research, 2005, Vol. 33, No. 6Id2 (2). The present study provides evidence linking C/EBPb
and Id2 in a gene network that is involved in lobuloalveolar
development at the pregnancy stage of the mammary gland.
Furthermore, RANKL, also known as osteoprotegerin ligand
(OPGL), has been shown to induce rapid nuclear translocation
ofC/EBPbfromthecytosolinmammaryepithelialcellsandto
regulate gene expression of b-casein (Csnb) gene, one of the
most abundant milk proteins (27). Therefore, it is conceivable
that an intracellular signaling cascade provoked by RANKL/
OPGL induces Id2 gene expression via C/EBPb during
lobuloalveolar development of the mammary gland during
pregnancy.
Besides a lactation defect, mice deﬁcient for Id2 display
multiple defects, mainly in the immune system, including
agenesis of lymph nodes and Peyer’s patches, impaired natural
killer cell development (14), selective loss of CD8a
+ dendritic
cells (28,29), Th2 dominance with an increased serum IgE
level (28,30) and reduction of intestinal lymphocytes (31).
These defects are not observed in C/EBPb-null mice. On
the contrary, C/EBPb-null mice exhibit impaired macrophage
function against bacteria and tumors (32,33), and are sterile as
a result of defective differentiation of ovarian granulosa cells
(34). These phenotypes are not shared with Id2-null mice,
although a fraction of Id2-null female mice show sterility
Figure 4. Transactivation of the Id2 promoter by C/EBPb is via CbE3. Mutant reporter plasmids were constructed based on pGL2-Id2/E. pGL2-Id2/ED1 lacks the
region containing both CbE2 and CbE3. Core sequences of CbE2 and CbE3 are deleted in pGL2-Id2/ED2 and pGL2-Id2/ED3, respectively. Deleted regions are
indicated by dashes. NIH3T3 cells were co-transfected with reporter plasmids and an internal control vector, pGL-renilla, together with pMSV-C/EBPb or pMSV-
mock.LuciferaseactivitywasdeterminedasintheexperimentsshowninFigure2.TransactivationoftherespectivereporterplasmidsbyC/EBPbispresentedasfold
induction of transactivation of pGL2-basic by C/EBPb. The mean and standard errors of the mean values from three separate assays are shown in the histograms.
Figure 5. Binding of C/EBPb to the Id2 promoter in vivo. The ChIP assay was
performedusingNIH3T3cellstransientlytransfectedwithemptyvector(lanes
1–5) or pC/EBPb-6Myc (lanes 6–10). The chromatin-associated DNA was
incubated without Ab (lanes 2 and 7) or with normal rabbit IgG (lanes 3
and 8), anti-Myc Ab (lanes 4 and 9), or anti-C/EBPb Ab (lanes 5 and 10).
Analiquot(2.5%)ofthetotalchromatinDNAwasusedforinput(lanes1and6).
Immunoprecipitates were subjected to PCR with a primer-pair specific to the
Id2 promoter that amplified a 311 bp fragment (upper panel). As a positive
control, PCR was carried out with a primer-pair specific to the Igf-1 promoter,
which amplified a 287 bp DNA fragment (lower panel). After 32 cycles of
amplification, PCR products were electrophoresed through a 3% agarose gel
and visualized by ethidium bromide staining.
Nucleic Acids Research, 2005, Vol. 33, No. 6 1931forunknownreasons(Y.Yokota,unpublisheddata).Currently,
therefore, the regulation of Id2 expression by C/EBPb seems
to be speciﬁc to mammary epithelial cells during lobuloalve-
olar development. However, we cannot exclude the possibility
that redundancy within the respective gene family com-
pensates for the function of the mutant genes and prevents
the mice from developing a defect in other cell types.
It has been shown that Id1, a founding member of the Id
gene family, is regulated by C/EBPb in pro-B cells (35,36).
Interestingly, IL-3-dependent expression of Id1 relies on
C/EBPb and Stat5 via the pro-B-cell enhancer element, and
deacetylation of C/EBPb by a histone deacetylase recruited by
Stat5 is required for transcription of Id1 (36). Since Stat5 is an
important transcription factor that is activated by prolactin
A
B
Figure 6. Id2expressioninmammaryglandsdeficientforC/EBPb.Epithelialcellsofwild-typeorC/EBPb-nullmammaryglandsweretransplantedintoprecleared
mammary glands of female Rag2-null mice. After 7 weeks, reconstituted mammary glands of non-pregnant and pregnant (10 d.p.c.) mice were subjected to whole
mount analysis and RNA purification. (A) Morphology of reconstituted mammary glands in the non-pregnant and pregnant mice. Reconstituted mammary glands
weredissectedout,mountedonaslideglassandstainedwithcarmine.Thegenotypeofadonorandthepregnantstateofarecipientareindicatedontheleftandthetop,
respectively. Both wild-type and C/EBPb-null mammary epithelial cells reconstituted the mammary gland of a recipient successfully and no significant difference
was observed in the non-pregnant state. In the mammary gland at 10 d.p.c., disturbed epithelial proliferation is evident in the gland reconstituted with C/EBPb-null
mammary epithelial cells. (B) Northern blot analysis of Id2 mRNA expression. RNA was purified from reconstituted mammary glands. Genotypes of transplanted
mammary epithelial cells are indicated on the top. The lower panel shows the representative data. The probes used are indicated on the left of the lower panels. The
upper panel shows the relative Id2 expression normalized by Cyk18 expression. The mean and standard error of the mean values obtained from three independent
samples are shown in the histograms.
1932 Nucleic Acids Research, 2005, Vol. 33, No. 6signaling, it will be interesting to know whether a similar
mechanism operates in the regulation of Id2 expression.
Among the molecules that are required for lobuloalveolar
development, some have been found to be involved in mam-
mary carcinogenesis, as might be predicted based on the fact
that robust cell proliferation occurs during lobuloalveolar
development. Cyclin D1 is a typical example: overexpression
of cyclin D1 protein is observed in more than half of human
breast cancers (37–39) and ampliﬁcation of the gene locus is
detected in 15–20% of such cancers (40). Through computa-
tional analysis ofthe expression patterns of genes across tumor
specimens, a recent study demonstrated that C/EBPb plays a
role in the consequences of cyclin D1 overexpression (41).Itis
thereforetemptingtospeculate thatthe cyclin D1-C/EBPb-Id2
axis is involved in the development of mammary tumors.
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